Related Experiment Video

Updated: Apr 1, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance

Mary Philip1, Andrea Schietinger1

  • 1Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Trends in Immunology
|October 7, 2015
PubMed

Insights

Cancer evolves resistance to therapy through non-genomic drivers, not just mutations. This study reveals dynamic changes in genetic, transcriptional, epigenetic, and immune landscapes during melanoma treatment resistance.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Cancer therapy resistance is a major clinical challenge, often attributed to genetic mutations.
  • Understanding the mechanisms driving treatment resistance is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the dynamic alterations in melanoma tumors resistant to MAPK inhibitors.
  • To identify the drivers of cancer evolution beyond traditional genomic mutations.

Main Methods:

  • Multidimensional analysis of genetic, transcriptional, epigenetic, and immune landscapes.
  • Comparison of baseline and therapy-resistant melanoma tumor samples.

Main Results:

  • Demonstrated that non-genomic factors play a significant role in cancer evolution and resistance.
  • Identified dynamic changes across multiple biological layers during the development of resistance.

Conclusions:

  • Cancer resistance to therapy is influenced by a complex interplay of genomic and non-genomic alterations.
  • Non-genomic drivers represent a novel target for overcoming melanoma treatment resistance.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69